Company news

Infant Bacterial Therapeutics AB news in 2024

Infant Bacterial Therapeutics AB's news releases, calls and decks from 2024, newest first.

View company

IBT_B: Phase 3 trial for IBP-9414 cut infant mortality, supporting IBT's regulatory push

November 14, 2024

IBT_B: Significant 27% mortality reduction observed in preterm infants, despite missed primary endpoints

September 3, 2024

IBT_B: Phase 3 trial for IBP-9414 completed; results expected Q3 2024 amid higher H1 losses

August 28, 2024

Decks in 2024